Abstract
Aim: The frequency of hyperlipidemia is high in diabetic patients, but medications are limited for controlling lipid abnormalities when chronic renal disease (CKD) advances. We evaluated the effects of rosuvastatin, one of the strong statins, on hyperlipidemia in type 2 diabetic patients receiving ethyl icosapentate (EPA).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
